The clinical trial application for the replication deficient monkeypox vaccine developed by Chinese biotechnology has been accepted
On July 13, the application for clinical trial of replication defective monkeypox vaccine independently developed by Sinopharm China Biotech Beijing Institute of Biological Products was officially accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration.Monkeypox is a kind of zoonotic viral disease caused by Monkeypox virus (MPXV), which is characterized by fever, rash and Lymphadenopathy...
Tech >>
Can Borui Biotech stand out in the treatment of lymphoma with the launch of its first biologically innovative drug, Zebedumab?
21st Century Business Herald reporter Zhu Yiyi reports from ShanghaiThe launch of this new drug is not only a major milestone in the development of Brilliant Biology, but also provides new treatment options for domestic lymphoma patients.Multiple indicators with significant clinical efficacyAccording to public information, lymphoma is one of the common hematological malignancies...
Tech >>